CRISPR Therapeutics Proposes New Appointment to the Board of Directors
October 16 2023 - 7:00AM
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company
focused on creating transformative gene-based medicines for serious
diseases, today announced it proposes to elect Sandy Mahatme, LL.M.
to its Board of Directors at the Company’s next annual general
meeting to be held in 2024.
“I am honored to welcome Sandy to our Board
during an important time in CRISPR Therapeutics’ continued
evolution,” said Samarth Kulkarni, Ph.D., Chief Executive Officer
and Chairman of the Board of CRISPR Therapeutics. “Sandy brings a
considerable breadth of experience to CRISPR Therapeutics gained
from his senior roles at industry-leading companies and has a
strong track record of success in finance, business development and
corporate strategy. His extensive experience and expertise will
make him an outstanding addition to our Board, and we look forward
to the valuable insights he will bring.”
Mr. Mahatme currently serves as President, Chief
Operating Officer and Chief Financial Officer of National
Resilience Inc., a technology-focused biomanufacturing company
dedicated to broadening access to complex medicines. He previously
served as Executive Vice President, Chief Financial Officer and
Chief Business Officer of Sarepta Therapeutics, Inc., a position he
held for almost eight years. Prior to those roles, he worked at
Celgene Corporation, where he served in various positions including
Senior Vice President of Corporate Development, Senior Vice
President of Finance, Corporate Treasurer and Head of Tax. Mr.
Mahatme served in senior roles in business development and
corporate finance at Pfizer, Inc. after starting his career at
Ernst & Young LLP. Mr. Mahatme earned Master of Laws degrees
from Cornell Law School and the New York University School of Law
and is a member of the New York State Bar Association. He has
previously held board positions at a number of biopharma companies
and currently holds a board position with Idorsia Pharmaceuticals
Ltd.
About CRISPR TherapeuticsCRISPR Therapeutics is
a leading gene editing company focused on developing transformative
gene-based medicines for serious diseases using its proprietary
CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing
technology that allows for precise, directed changes to genomic
DNA. CRISPR Therapeutics has established a portfolio of therapeutic
programs across a broad range of disease areas including
hemoglobinopathies, oncology, regenerative medicine and rare
diseases. To accelerate and expand its efforts, CRISPR Therapeutics
has established strategic partnerships with leading companies
including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR
Therapeutics AG is headquartered in Zug, Switzerland, with its
wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and
R&D operations based in Boston, Massachusetts and San
Francisco, California, and business offices in London, United
Kingdom. For more information, please visit www.crisprtx.com.
CRISPR THERAPEUTICS® word mark and design logo
are registered trademarks of CRISPR Therapeutics AG. All other
trademarks and registered trademarks are the property of their
respective owners.
Investor Contact:Susan
Kim+1-617-315-4600susan.kim@crisprtx.com
Media Contact:Rachel
Eides+1-617-315-4493rachel.eides@crisprtx.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2024 to May 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From May 2023 to May 2024